Line 4: |
Line 4: |
| __TOC__ | | __TOC__ |
| | | |
− | ==Translocations Long List== | + | ==Translocations== |
| | | |
| {| class="wikitable" | | {| class="wikitable" |
Line 30: |
Line 30: |
| |- | | |- |
| |[[t(1;5)(q22;q33)]] | | |[[t(1;5)(q22;q33)]] |
− | |[[MPD with eosinophilia]],[[ CEL]],[[ B-ALL]] | + | |[[MPD]],[[ CEL]],[[ B-ALL]] |
| |[[PDE4DIP-PDGFRB]] | | |[[PDE4DIP-PDGFRB]] |
| |- | | |- |
Line 42: |
Line 42: |
| |- | | |- |
| |[[t(1;14)(q21;q32)]] | | |[[t(1;14)(q21;q32)]] |
− | |[[B-ALL]],[[ NHL]] | + | |[[B-ALL]],[[NHL]] |
| |[[IGH-BCL9]],[[IGH-FCGR2B]],[[IGH-FCRL4]],[[IGH-MUC1]] | | |[[IGH-BCL9]],[[IGH-FCGR2B]],[[IGH-FCRL4]],[[IGH-MUC1]] |
| |- | | |- |
Line 58: |
Line 58: |
| |- | | |- |
| |[[t(2;5)(p23;q35)]] | | |[[t(2;5)(p23;q35)]] |
− | |[[ALCL]],[[ NHL]] | + | |[[ALCL]],[[NHL]] |
| |[[NPM1-ALK]] | | |[[NPM1-ALK]] |
| |- | | |- |
| |[[t(2;8)(p12;q24.1)]] | | |[[t(2;8)(p12;q24.1)]] |
− | |[[BL]],[[ B-ALL]],[[ NHL ]] | + | |[[BL]],[[ B-ALL]],[[NHL]] |
| |[[MYC]] | | |[[MYC]] |
| |- | | |- |
Line 73: |
Line 73: |
| | | | | |
| |- | | |- |
− | |[[Translocation t(3;3)(q21;q26.2) and Inversion inv(3)(q21q26.2)|t(3;3)(q21;q26.2) ]] | + | |[[Translocation t(3;3)(q21;q26.2) and Inversion inv(3)(q21q26.2)|t(3;3)(q21;q26.2)]] |
| |[[MDS]],[[AML]] | | |[[MDS]],[[AML]] |
| |[[RPN1-MECOM(EVI1)]] | | |[[RPN1-MECOM(EVI1)]] |
Line 98: |
Line 98: |
| |- | | |- |
| |[[t(4;5;5)(q23;q31;q33)]] | | |[[t(4;5;5)(q23;q31;q33)]] |
− | |[[chronic basophilic leukemia]] | + | |[[Chronic Basophilic Leukemia]] |
| |[[PRKG2-PDGFRB]] | | |[[PRKG2-PDGFRB]] |
| |- | | |- |
Line 114: |
Line 114: |
| |- | | |- |
| |[[t(5;12)(q33;q24)]] | | |[[t(5;12)(q33;q24)]] |
− | |[[MPD with eosinophilia ]] | + | |[[MPD]] |
| |[[GIT2-PDGFRB]] | | |[[GIT2-PDGFRB]] |
| |- | | |- |
| |[[t(5;12)(q33;p13)]] | | |[[t(5;12)(q33;p13)]] |
− | |[[CMML]],[[ MDS]],[[ MPD]] | + | |[[CMML]],[[MDS]],[[MPD]] |
| |[[ETV6(TEL)-PDGFRB]] | | |[[ETV6(TEL)-PDGFRB]] |
| |- | | |- |
| |[[t(5;14)(q33;q24)]] | | |[[t(5;14)(q33;q24)]] |
− | |[[MPD]],[[ atypical MPD]] | + | |[[MPD]],[[MPD]] |
| |[[NIN-PDGFRB]] | | |[[NIN-PDGFRB]] |
| |- | | |- |
Line 130: |
Line 130: |
| |- | | |- |
| |[[t(5;15)(q33;q22)]] | | |[[t(5;15)(q33;q22)]] |
− | |[[CMML atypical MPD]] | + | |[[CMML]],[[MPD]] |
| |[[TP53BP1-PDGFRB]] | | |[[TP53BP1-PDGFRB]] |
| |- | | |- |
Line 142: |
Line 142: |
| |- | | |- |
| |[[der(5;17)(p10;q10)]] | | |[[der(5;17)(p10;q10)]] |
− | |[[MDS]],[[ AML]] | + | |[[MDS]],[[AML]] |
| |[[NPM1(NPM)-RARA]] | | |[[NPM1(NPM)-RARA]] |
| |- | | |- |
Line 150: |
Line 150: |
| |- | | |- |
| |[[t(5;17)(q33;p13)]] | | |[[t(5;17)(q33;p13)]] |
− | |[[CMML]],[[ atypical MPD]] | + | |[[CMML]],[[MPD]] |
| |[[RABEP1-PDGFRB ]] | | |[[RABEP1-PDGFRB ]] |
| |- | | |- |
Line 162: |
Line 162: |
| |- | | |- |
| |[[t(6;11)(q27;q23) ]] | | |[[t(6;11)(q27;q23) ]] |
− | |[[AML]],[[ t-AML]],[[ T-ALL]] | + | |[[AML]],[[ t-AML]],[[T-ALL]] |
| |[[KMT2A-MLLT4]] | | |[[KMT2A-MLLT4]] |
| |- | | |- |
Line 173: |
Line 173: |
| |[[IGH-MYC]] | | |[[IGH-MYC]] |
| |- | | |- |
− | |[[t(8;16)(p11.2;p13.3) A]] | + | |[[t(8;16)(p11.2;p13.3)]] |
| |[[AML]],[[t-MDS]] | | |[[AML]],[[t-MDS]] |
| |[[KAT6A(MYST3)-CREBBP(CBP)]] | | |[[KAT6A(MYST3)-CREBBP(CBP)]] |
| |- | | |- |
| |[[t(8;21)(q22;q22) A ]] | | |[[t(8;21)(q22;q22) A ]] |
− | |[[AML M2 mostly]],[[ rarely M1]],[[ M4]] | + | |[[AML]] |
| |[[RUNX1(AML)-RUNX1T1(ETO)]] | | |[[RUNX1(AML)-RUNX1T1(ETO)]] |
| |- | | |- |
| |[[t(8;22)(q24.1;q11.2) ]] | | |[[t(8;22)(q24.1;q11.2) ]] |
− | |[[BL]],[[ B-ALL]],[[ NHL]],[[ MM]] | + | |[[BL]],[[ B-ALL]],[[NHL]],[[ MM]] |
| |[[IGL-MYC]] | | |[[IGL-MYC]] |
| |- | | |- |
Line 194: |
Line 194: |
| |- | | |- |
| |[[t(9;14)(p13;q32)]] | | |[[t(9;14)(p13;q32)]] |
− | |[[MM]],[[CLL]],[[DLBCL]],[[ FL]],[[MCL splenic MZL]] | + | |[[MM]],[[CLL]],[[DLBCL]],[[FL]],[[MCL splenic MZL]] |
| |[[PAX5-IGH]] | | |[[PAX5-IGH]] |
| |- | | |- |
| |[[t(9;22)(q34;q11.2)]] | | |[[t(9;22)(q34;q11.2)]] |
− | |[[CML]],[[ B-ALL]],[[ T-ALL]] | + | |[[CML]],[[ B-ALL]],[[T-ALL]] |
| |[[ABL1(ABL)-BCR]] | | |[[ABL1(ABL)-BCR]] |
| |- | | |- |
| |[[t(11;14)(q13;q32)]] | | |[[t(11;14)(q13;q32)]] |
| |[[MCL]],[[ MM]] | | |[[MCL]],[[ MM]] |
− | |[[CCND1(BCL1)- IGH]] | + | |[[IGH-CCND1]] |
| |- | | |- |
| |[[t(11;14)(q23;q32)]] | | |[[t(11;14)(q23;q32)]] |
− | |[[t-AML]] | + | |[[AML]] |
| |[[KMT2A-KIAA0284]] | | |[[KMT2A-KIAA0284]] |
| |- | | |- |
Line 356: |
Line 356: |
| |- | | |- |
| |[[i(11)(q10) ]] | | |[[i(11)(q10) ]] |
− | |[[AML M2]],[[AML M4]],[[ MDS]] | + | |[[AML]],[[AML]],[[ MDS]] |
| | | | | |
| |- | | |- |
| |[[i(17)(q10)]] | | |[[i(17)(q10)]] |
− | |[[MDS]],[[ MPD]],[[ AML]],[[ CML]],[[ B-ALL]],[[ CLL]],[[ Hodgkin and NHL]] | + | |[[MDS]],[[ MPD]],[[ AML]],[[ CML]],[[ B-ALL]],[[CLL]],[[ Hodgkin and NHL]] |
| | | | | |
| |- | | |- |
| |[[i(21)(q10)]] | | |[[i(21)(q10)]] |
− | |[[B-ALL]],[[ MDS]],[[ NHL]],[[ AML]],[[ CMML]] | + | |[[B-ALL]],[[ MDS]],[[ NHL]],[[AML]],[[ CMML]] |
| | | | | |
| |- | | |- |
| |[[idic(X)(q13)]] | | |[[idic(X)(q13)]] |
− | |[[AML M1]],[[ M2]],[[ M4]],[[ MDS]],[[ RARS]] | + | |[[AML]],[[MDS]],[[RARS]] |
| |[[XIST]] | | |[[XIST]] |
| |} | | |} |
Line 583: |
Line 583: |
| | | | | |
| |- | | |- |
− | |[[del(20)(q11.2q13.1) | + | |[[del(20)(q11.2q13.1)]] |
| + | | |
| + | | |
| + | |- |
| |[[del(20)(q11.2q13.3)]] | | |[[del(20)(q11.2q13.3)]] |
| |[[AML]],[[MDS]],[[MPD]] | | |[[AML]],[[MDS]],[[MPD]] |
| + | | |
| |- | | |- |
| |[[ider(20)(p11.1)del(20)(q11.2q13.3)]] | | |[[ider(20)(p11.1)del(20)(q11.2q13.3)]] |
Line 632: |
Line 636: |
| |- | | |- |
| |[[+15]] | | |[[+15]] |
− | |Age related when sole anomaly or with -Y | + | |[[Age Related]] when sole anomaly or with [[-Y]] |
| |- | | |- |
| |[[+19]] | | |[[+19]] |
Line 647: |
Line 651: |
| |- | | |- |
| |[[-Y ]] | | |[[-Y ]] |
− | |age related when sole anomaly | + | |[[Age Related]] when sole anomaly |
| | | |
| |} | | |} |